These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9448481)

  • 1. Blood safety and Creutzfeldt-Jakob disease.
    Wkly Epidemiol Rec; 1998 Jan 2-9; 73(1-2):6-7. PubMed ID: 9448481
    [No Abstract]   [Full Text] [Related]  

  • 2. Creutzfeldt-Jakob disease and blood products: FDA policy.
    Fratantoni JC
    Biologicals; 1998 Jun; 26(2):133-4. PubMed ID: 9811520
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products.
    Prowse C; Cuthbertson B; Turner M
    Haemophilia; 2011 Jul; 17(4):703. PubMed ID: 21362112
    [No Abstract]   [Full Text] [Related]  

  • 4. vCJD and blood transfusion in the United Kingdom.
    Hewitt P
    Transfus Clin Biol; 2006 Nov; 13(5):312-6. PubMed ID: 17188541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
    Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of variant CJD on transfusion practices in the UK.
    Boulton F
    Transfus Apher Sci; 2003 Apr; 28(2):107-16. PubMed ID: 12679113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creutzfeldt-Jakob disease and the risk from blood or blood products.
    Will RG; Kimberlin RH
    Vox Sang; 1998; 75(3):178-80. PubMed ID: 9852403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucoreduction and variant Creutzfeldt-Jakob disease.
    Darabi K; Dzik WH; Stowell CP; Saito Y
    Transfus Med; 2005 Aug; 15(4):335. PubMed ID: 16101813
    [No Abstract]   [Full Text] [Related]  

  • 9. Symposium on prions and transfusion safety.
    Coste J
    Transfus Clin Biol; 2013 Sep; 20(4):393-4. PubMed ID: 23928184
    [No Abstract]   [Full Text] [Related]  

  • 10. Transfusion-related vCJD: prevention strategies for prion transmission.
    Holland PV
    Lijec Vjesn; 2007 May; 129 Suppl 3():46. PubMed ID: 18959066
    [No Abstract]   [Full Text] [Related]  

  • 11. Transfusion safety with regards to prions: ethical, legal and societal considerations.
    Turner M
    Transfus Clin Biol; 2006 Nov; 13(5):317-9. PubMed ID: 17196417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to reduce transfusion acquired vCJD.
    Wallis JP
    Transfus Med; 2011 Feb; 21(1):1-6. PubMed ID: 21070399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Creutzfeldt-Jakob disease transmitted in blood? Is the absence of evidence of risk evidence of the absence of risk?
    Ricketts MN
    CMAJ; 1997 Nov; 157(10):1367-70. PubMed ID: 9371066
    [No Abstract]   [Full Text] [Related]  

  • 14. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 15. A commentary on variant Creutzfeld-Jacob disease.
    Hoots K
    Haemophilia; 2010 Mar; 16(2):238-9. PubMed ID: 20487441
    [No Abstract]   [Full Text] [Related]  

  • 16. Creutzfeldt-Jakob disease and transfusion safety: tilting at icebergs?
    Dodd RY; Sullivan MT
    Transfusion; 1998 Mar; 38(3):221-3. PubMed ID: 9563399
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aspects of the risks associated with vCJK from plasma derivatives from human plasma].
    Burger R; Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):648-9. PubMed ID: 19557456
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality and risk management: the commitment of the Council of Europe.
    Bopp KF
    Transfus Clin Biol; 2001 Jun; 8(3):218-9. PubMed ID: 11499962
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
    Martin M; Trouvin JH
    Transfus Clin Biol; 2013 Sep; 20(4):398-404. PubMed ID: 23910008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.